For example, in Australia, separate funding became available for Herceptin, and a similar arrangement is available in France. In Germany, cancer drugs are paid on a DRG basis or through “specific additional payments” (Zusatzentgelte). In the Netherlands, the pharmacy units in hospitals were previously responsible for pharmaceutical purchases, and hospitals with a pharmacy unit that managed to purchase innovative drugs at lower prices were able to use these drugs more than other hospitals, leading to cross-hospital variations in the availability of expensive pharmaceuticals. But due to pressure from patient groups, in 2002/03 the Ministry of Health became responsible for 80% of the costs related to the purchase of expensive pharmaceuticals to insurance companies, with the rest paid by the hospitals and pharmacy.